Central nervous system alterations caused by infection with the human respiratory syncytial virus

Reviews in Medical Virology

Volumn 24, Issue 6, 2014, Pages 407-419

  Bohmwald, Karen ^a   Espinoza, Janyra A ^a   González, Pablo A ^a   Bueno, Susan M ^a,d   Riedel, Claudia A ^b   Kalergis, Alexis M ^a,c,d  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b UNIVERSIDAD ANDRÉS BELLO   (Chile)

^c PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^d INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PALIVIZUMAB; RESPIRATORY SYNCYTIAL VIRUS VACCINE;

APNEA; BRAIN DISEASE; CENTRAL NERVOUS SYSTEM; CLINICAL FEATURE; DISEASE ASSOCIATION; FUNCTIONAL DISEASE; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; INFECTION PREVENTION; NEUROLOGIC DISEASE; NONHUMAN; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; SEIZURE; STRABISMUS; VACCINATION; VIRION; VIRUS ENTRY; VIRUS PATHOGENESIS; VIRUS REPLICATION; VIRUS TRANSMISSION; ANIMAL; CENTRAL NERVOUS SYSTEM DISEASES; COMPLICATION; PHYSIOLOGY; VIROLOGY;

ANIMALS; CENTRAL NERVOUS SYSTEM DISEASES; HUMANS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN;

EID: 84926021827     PISSN: 10529276     EISSN: 10991654     Source Type: Journal    
DOI: 10.1002/rmv.1813     Document Type: Review

References (118)

1. Calvo C, et al. Multiple simultaneous viral infections in infants with acute respiratory tract infections in Spain. Journal of Clinical Virology 2008; 42(3): 268-72.
2. Ogra PL. Respiratory syncytial virus: the virus, the disease and the immune response. Paediatric Respiratory Reviews 2004; 5 Suppl A: S119-26.
3. Gonzalez PA, et al. Respiratory syncytial virus impairs T cell activation by preventing synapse assembly with dendritic cells. Proceedings of the National Academy of Sciences of the United States of America 2008; 105(39): 14999-5004.
4. Bueno SM, et al. Host immunity during RSV pathogenesis. International Immunopharmacology, 2008; 8(10): 1320-9.
5. Collins PL, Melero JA. Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Research 2011; 162(1-2): 80-99.
6. Sweetman LL, et al. Neurologic complications associated with respiratory syncytial virus. Pediatric Neurology 2005; 32(5): 307-10.
7. Boyce TG, et al. Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. Journal of Pediatrics 2000; 137(6): 865-70.
8. Wang EE, et al. Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study of admission and management variation in patients hospitalized with respiratory syncytial viral lower respiratory tract infection. Journal of Pediatrics 1996; 129(3): 390-5.
9. Navas L, et al. Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. Pediatric Investigators Collaborative Network on Infections in Canada. Journal of Pediatrics 1992; 121(3): 348-54.
10. Nair H, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010; 375(9725): 1545-55.
11. Paramore LC, et al. Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases. PharmacoEconomics 2004; 22(5): 275-84.
12. Halfhide CP, et al. Respiratory syncytial virus binds and undergoes transcription in neutrophils from the blood and airways of infants with severe bronchiolitis. Journal of Infectious Diseases 2011; 204(3): 451-8.
13. Hall CB, et al. Infectivity of respiratory syncytial virus by various routes of inoculation. Infection and Immunity 1981; 33(3): 779-83.
14. Storey S. Respiratory syncytial virus market. Nature Reviews Drug Discovery 2010; 9(1):15-6.
15. Dudas RA, Karron RA, Respiratory syncytial virus vaccines. Clinical Microbiology Reviews 1998; 11(3): 430-9.
16. van Drunen Littel-van den Hurk S, Watkiss ER. Pathogenesis of respiratory syncytial virus. Curr Opin Virol 2012; 2(3): 300-5.
17. Gonzalez PA, et al. Impairment of T cell immunity by the respiratory syncytial virus: targeting virulence mechanisms for therapy and prophylaxis. Current Medicinal Chemistry 2009; 16(34): 4609-25.
18. Bont L, et al. Natural reinfection with respiratory syncytial virus does not boost virus-specific T-cell immunity. Pediatric Research 2002; 52(3): 363-7.
19. Rudraraju R, et al. Respiratory syncytial virus: current progress in vaccine development. Viruses 2013; 5(2): 577-94.
20. Lanari M, et al. The use of humanized monoclonal antibodies for the prevention of respiratory syncytial virus infection. Clinical and Developmental Immunology 2013; 2013: 359683.
21. Lanari M, Silvestri M, Rossi GA. Clinical and pharmacological aspects of immunoprophylaxis for respiratory syncytial virus infection in high-risk infants. Current Drug Metabolism 2013; 14(2): 216-25.
22. Eisenhut M. Extrapulmonary manifestations of severe respiratory syncytial virus infection--a systematic review. Critical Care 2006; 10(4): R107.
23. Esposito S, et al. Altered cardiac rhythm in infants with bronchiolitis and respiratory syncytial virus infection. BMC Infectious Diseases 2010; 10: 305.
24. Kirin BK, Topic RZ, Dodig S. Hepatitis during respiratory syncytial virus infection--a case report. Biochem Med (Zagreb) 2013; 23(1): 112-6.
25. Wong KT. Emerging epidemic viral encephalitides with a special focus on henipaviruses. Acta Neuropathologica 2010; 120(3): 317-25.
26. Reuter D, Schneider-Schaulies J. Measles virus infection of the CNS: human disease, animal models, and approaches to therapy. Medical Microbiology and Immunology 2010; 199(3): 261-71.
27. McCarthy VP, Zimmerman AW, Miller CA. Central nervous system manifestations of parainfluenza virus type 3 infections in childhood. Pediatric Neurology 1990; 6(3): 197-201.
28. Arnold JC, et al. Human metapneumovirus associated with central nervous system infection in children. Pediatric Infectious Disease Journal 2009; 28(12): 1057-60.
29. Munster VJ, et al. Rapid Nipah virus entry into the central nervous system of hamsters via the olfactory route. Science Reports 2012; 2: 736.
30. Weingartl H, et al. Invasion of the central nervous system in a porcine host by nipah virus. Journal of Virology 2005; 79(12): 7528-34.
31. Lay MK, et al. Advances in understanding respiratory syncytial virus infection in airway epithelial cells and consequential effects on the immune response. Microbes and Infection 2013; 15(3): 230-42.
32. Hacking D, Hull J. Respiratory syncytial virus--viral biology and the host response. Journal of Infection 2002; 45(1): 18-24.
33. Hastie ML, et al. The human respiratory syncytial virus non-structural protein 1 regulates type I and type II interferon pathways. Molecular and Cellular Proteomics 2012.
34. Mastrangelo P, Hegele RG. RSV fusion: time for a new model. Viruses 2013; 5(3): 873-85.
35. Harcourt J, et al. Respiratory syncytial virus G protein and G protein CX3C motif adversely affect CX3CR1+ T cell responses. Journal of Immunology 2006; 176(3): 1600-8.
36. Haynes LM, et al. Therapeutic monoclonal antibody treatment targeting respiratory syncytial virus (RSV) G protein mediates viral clearance and reduces the pathogenesis of RSV infection in BALB/c mice. Journal of Infectious Diseases 2009; 200(3): 439-47.
37. Radu GU, et al. Prophylactic treatment with a G glycoprotein monoclonal antibody reduces pulmonary inflammation in respiratory syncytial virus (RSV)-challenged naive and formalin-inactivated RSV-immunized BALB/c mice. Journal of Virology 2010; 84(18): 9632-6.
38. Karron RA, et al. Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant. Proceedings of the National Academy of Sciences of the United States of America 1997; 94(25): 13961-6.
39. Bawage SS, et al. Recent Advances in Diagnosis, Prevention, and Treatment of Human Respiratory Syncytial Virus. Adv Virol 2013; 2013: 595768.
40. Sun Z, et al. Respiratory syncytial virus entry inhibitors targeting the F protein. Viruses 2013; 5(1): 211-25.
41. Triantafilou K, et al. Human respiratory syncytial virus viroporin SH: a viral recognition pathway used by the host to signal inflammasome activation. Thorax 2013; 68(1): 66-75.
42. Gan SW, et al. Structure and ion channel activity of the human respiratory syncytial virus (hRSV) small hydrophobic protein transmembrane domain. Protein Science 2008; 17(5): 813-20.
43. Teng MN, Whitehead SS, Collins PL. Contribution of the respiratory syncytial virus G glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo. Virology 2001; 289(2): 283-96.
44. Lotz MT, Peebles RS Jr, Mechanisms of respiratory syncytial virus modulation of airway immune responses. Current Allergy and Asthma Reports 2012; 12(5): 380-7.
45. Gomez RS, et al. Respiratory syncytial virus detection in cells and clinical samples by using three new monoclonal antibodies. Journal of Medical Virology 2013.
46. de Graaff PM, et al., Respiratory syncytial virus infection of monocyte-derived dendritic cells decreases their capacity to activate CD4 T cells. Journal of Immunology 2005; 175(9): 5904-11.
47. Zhang L, et al. Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology. Journal of Virology 2002; 76(11): 5654-66.
48. Harpen M, et al. Mutational analysis reveals a noncontractile but interactive role of actin and profilin in viral RNA-dependent RNA synthesis. Journal of Virology 2009; 83(21): 10869-76.
49. Ghildyal R, et al. Nuclear import of the respiratory syncytial virus matrix protein is mediated by importin beta1 independent of importin alpha. Biochemistry 2005; 44(38): 12887-95.
50. Rodriguez L, et al. Human respiratory syncytial virus matrix protein is an RNA-binding protein: binding properties, location and identity of the RNA contact residues. Journal of General Virology 2004; 85(Pt 3): 709-19.
51. Ghildyal R, et al. The matrix protein of Human respiratory syncytial virus localises to the nucleus of infected cells and inhibits transcription. Archives of Virology 2003; 148(7): 1419-29.
52. Ghildyal R, et al. The respiratory syncytial virus matrix protein possesses a Crm1-mediated nuclear export mechanism. Journal of Virology 2009; 83(11): 5353-62.
53. Marty A, et al. Association of matrix protein of respiratory syncytial virus with the host cell membrane of infected cells. Archives of Virology 2004; 149(1): 199-210.
54. Utley TJ, et al., Respiratory syncytial virus uses a Vps4-independent budding mechanism controlled by Rab11-FIP2. Proceedings of the National Academy of Sciences of the United States of America 2008; 105(29): 10209-14.
55. Li XQ, et al. Respiratory syncytial virus (RSV) infects neuronal cells and processes that innervate the lung by a process involving RSV G protein. Journal of Virology 2006; 80(1): 537-40.
56. Collarini EJ, et al. Potent high-affinity antibodies for treatment and prophylaxis of respiratory syncytial virus derived from B cells of infected patients. Journal of Immunology 2009; 183(10): 6338-45.
57. Bueno SM, et al. Local cytokine response upon respiratory syncytial virus infection. Immunology Letters 2011; 136(2): 122-9.
58. Avendano LF, Palomino MA, Larranaga C. Surveillance for respiratory syncytial virus in infants hospitalized for acute lower respiratory infection in Chile (1989 to 2000). Journal of Clinical Microbiology 2003; 41(10): 4879-82.
59. Munir S, et al. Respiratory syncytial virus interferon antagonist NS1 protein suppresses and skews the human T lymphocyte response. PLoS Pathogens 2011; 7(4): e1001336.
60. Olson MR, Hartwig SM, Varga SM. The number of respiratory syncytial virus (RSV)-specific memory CD8 T cells in the lung is critical for their ability to inhibit RSV vaccine-enhanced pulmonary eosinophilia. Journal of Immunology 2008; 181(11): 7958-68.
61. Varga SM, et al., Immunopathology in RSV infection is mediated by a discrete oligoclonal subset of antigen-specific CD4(+) T cells. Immunity 2001; 15(4): 637-46.
62. Wan YY, Flavell RA. How diverse--CD4 effector T cells and their functions. Journal of Molecular Cell Biology 2009; 1(1): 20-36.
63. Singleton R, et al. Inability To Evoke a Long-Lasting Protective Immune Response to Respiratory Syncytial Virus Infection in Mice Correlates with Ineffective Nasal Antibody Responses. Journal of Virology 2003; 77(21): 11303-11.
64. Vallbracht S, Unsold H, Ehl S. Functional impairment of cytotoxic T cells in the lung airways following respiratory virus infections. European Journal of Immunology 2006; 36(6): 1434-42.
65. Akins PT, et al. H1N1 encephalitis with malignant edema and review of neurologic complications from influenza. Neurocritical Care 2010; 13(3): 396-406.
66. Gonzalez PA, et al., Respiratory syncytial virus infection and immunity. Reviews in Medical Virology 2012.
67. Gonzalez PA, et al. Understanding respiratory syncytial virus infection to improve treatment and immunity. Current Molecular Medicine 2013; 13(7): 1122-39.
68. Bueno SM, et al. Protective T cell immunity against respiratory syncytial virus is efficiently induced by recombinant BCG. Proceedings of the National Academy of Sciences of the United States of America 2008; 105(52): 20822-7.
69. Kho N, et al. Respiratory syncytial virus infection and neurologic abnormalities: retrospective cohort study. Journal of Child Neurology 2004; 19(11): 859-64.
70. Hall CB, Simoes EA, Anderson LJ. Clinical and epidemiologic features of respiratory syncytial virus. Current Topics in Microbiology and Immunology 2013; 372: 39-57.
71. Roymans D, Koul A. Treatment of Respiratory Syncytial Virus Infection: Past, Present and Future. Human Respiratory Syncytial Virus Infection, Resch B (ed). ISBN: 978-953-307-718-5, InTech, DOI: 10.5772/26528. 2011.
72. Mohapatra SS, et al. Experimental forms of allergen immunotherapy with modified allergens and adjuvants. Clinical Allergy and Immunology 2008; 21: 393-413.
73. Thomsen SF, et al. Exploring the association between severe respiratory syncytial virus infection and asthma: a registry-based twin study. American Journal of Respiratory and Critical Care Medicine 2009; 179(12): 1091-7.
74. Gut W, et al. RSV respiratory infection in children under 5 y.o.--dynamics of the immune response Th1/Th2 and IgE. Przeglad Epidemiologiczny 2013; 67(1): 17-22, 105-9.
75. Lee HC, et al. Thymic stromal lymphopoietin is induced by respiratory syncytial virus-infected airway epithelial cells and promotes a type 2 response to infection. Journal of Allergy and Clinical Immunology 2012; 130(5): 1187-1196e5.
76. Becker Y. Respiratory syncytial virus (RSV) evades the human adaptive immune system by skewing the Th1/Th2 cytokine balance toward increased levels of Th2 cytokines and IgE, markers of allergy--a review. Virus Genes 2006; 33(2): 235-52.
77. Whimbey E, et al. Respiratory syncytial virus pneumonia in hospitalized adult patients with leukemia. Clinical Infectious Diseases 1995; 21(2): 376-9.
78. Torres JP, et al. Respiratory syncytial virus (RSV) RNA loads in peripheral blood correlates with disease severity in mice. Respiratory Research 2010; 11: 125.
79. Houben ML, et al. Disease severity and viral load are correlated in infants with primary respiratory syncytial virus infection in the community. Journal of Medical Virology 2010; 82(7): 1266-71.
80. Borchers AT, et al. Respiratory syncytial virus-a comprehensive review. Clinical Reviews in Allergy and Immunology 2013; 45(3): 331-79.
81. Morichi S, et al. Classification of acute encephalopathy in respiratory syncytial virus infection. Journal of Infection and Chemotherapy 2011; 17(6): 776-81.
82. Millichap JJ, Wainwright MS. Neurological complications of respiratory syncytial virus infection: case series and review of literature. Journal of Child Neurology 2009; 24(12): 1499-503.
83. Eisenhut M. Cerebral involvement in respiratory syncytial virus disease. Brain Dev 2007; 29(7): 454.
84. Antonucci R, Fanos V. Acute encephalopathy associated with respiratory syncytial virus infections in childhood. A literature review. Minerva Pediatrica 2005; 57(3): 137-42.
85. Kawashima H, et al. Production of chemokines in respiratory syncytial virus infection with central nervous system manifestations. Journal of Infection and Chemotherapy 2012; 18(6): 827-31.
86. Otake Y, et al. Elevated CSF IL-6 in a patient with respiratory syncytial virus encephalopathy. Brain Dev 2007; 29(2): 117-20.
87. Kawashima H, et al., Production of chemokines in respiratory syncytial virus infection with central nervous system manifestations. Journal of Infection and Chemotherapy 2012; 18(6): 827-31.
88. Kawashima H, et al. Production of chemokines in respiratory syncytial virus infection with central nervous system manifestations. Journal of Infection and Chemotherapy 2012; 18(6): 827-31.
89. Lindgren C. Grogaard J. Reflex apnoea response and inflammatory mediators in infants with respiratory tract infection. Acta Paediatrica 1996; 85(7): 798-803.
90. Rayyan M, et al. Characteristics of respiratory syncytial virus-related apnoea in three infants. Acta Paediatrica 2004; 93(6): 847-9.
91. Lindgren C, et al. Respiratory syncytial virus infection enhances the response to laryngeal chemostimulation and inhibits arousal from sleep in young lambs. Acta Paediatrica 1996; 85(7): 789-97.
92. Piedimonte G. Pathophysiological mechanisms for the respiratory syncytial virus-reactive airway disease link. Respiratory Research 2002; 3 Suppl 1: S21-5.
93. Zlateva KT, Van Ranst M. Detection of subgroup B respiratory syncytial virus in the cerebrospinal fluid of a patient with respiratory syncytial virus pneumonia. Pediatric Infectious Disease Journal 2004; 23(11): 1065-6.
94. Graham BS, Johnson TR, Peebles RS. Immune-mediated disease pathogenesis in respiratory syncytial virus infection. Immunopharmacology 2000. 48(3): 237-47.
95. Manoha C, et al. Epidemiological and clinical features of hMPV, RSV and RVs infections in young children. Journal of Clinical Virology 2007; 38(3): 221-6.
96. Rohwedder A, et al. Detection of respiratory syncytial virus RNA in blood of neonates by polymerase chain reaction. Journal of Medical Virology 1998; 54(4): 320-7.
97. Yui I, et al. Detection of human respiratory syncytial virus sequences in peripheral blood mononuclear cells. Journal of Medical Virology 2003; 70(3): 481-9.
98. Torres JP, et al. Respiratory Syncytial Virus (RSV) RNA loads in peripheral blood correlates with disease severity in mice. Respiratory Research 2010; 11: 125.
99. Angel Rico M, et al. Human respiratory syncytial virus infects and induces activation markers in mouse B lymphocytes. Immunology and Cell Biology 2009. 87(4): 344-50.
100. Johnson TR, et al. Primary human mDC1, mDC2, and pDC dendritic cells are differentially infected and activated by respiratory syncytial virus. PLoS One 2011; 6(1): e16458.
101. Espinoza JA, et al. Impaired learning resulting from Respiratory Syncytial Virus infection. Proceedings of the National Academy of Sciences of the United States of America 2013.
102. Deacon RM. Digging and marble burying in mice: simple methods for in vivo identification of biological impacts. Nature Protocols 2006; 1(1): 122-4.
103. Vorhees CV, Williams MT. Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nature Protocols 2006; 1(2): 848-58.
104. D'Hooge R, De Deyn PP. Applications of the Morris water maze in the study of learning and memory. Brain Research. Brain Research Reviews 2001; 36(1): 60-90.
105. Puchkov GF, Min'kovich BM. Respiratory syncytial infection in a child complicated by interstitial myocarditis with fatal outcome. Arkhiv Patologii 1972; 34(1): 70-3.
106. Donnerstein RL, et al. Complex atrial tachycardias and respiratory syncytial virus infections in infants. Journal of Pediatrics 1994; 125(1): 23-8.
107. Menchise A. Myocarditis in the setting of RSV bronchiolitis. Fetal and Pediatric Pathology 2013; 30(1): 64-8.
108. Eisenhut M, Thorburn K. Hepatitis associated with severe respiratory syncytial virus-positive lower respiratory tract infection. Scandinavian Journal of Infectious Diseases 2002; 34(3): 235.
109. Hanna S, et al. Incidence of hyponatraemia and hyponatraemic seizures in severe respiratory syncytial virus bronchiolitis. Acta Paediatrica 2003; 92(4): 430-4.
110. Chang J. Current progress on development of respiratory syncytial virus vaccine. BMB Reports 2012; 44(4): 232-7.
111. Luongo C, et al. Increased genetic and phenotypic stability of a promising live-attenuated respiratory syncytial virus vaccine candidate by reverse genetics. Journal of Virology 2012; 86(19): 10792-804.
112. Shafique M, Wilschut J, de Haan A. Induction of mucosal and systemic immunity against respiratory syncytial virus by inactivated virus supplemented with TLR9 and NOD2 ligands. Vaccine 2012; 30(3): 597-606.
113. Cautivo KM, et al. Efficient lung recruitment of respiratory syncytial virus-specific Th1 cells induced by recombinant bacillus Calmette-Guerin promotes virus clearance and protects from infection.Journal of Immunology 2010; 185(12): 7633-45.
114. Luongo C, et al. Respiratory syncytial virus modified by deletions of the NS2 gene and amino acid S1313 of the L polymerase protein is a temperature-sensitive, live-attenuated vaccine candidate that is phenotypically stable at physiological temperature. Journal of Virology 2012; 87(4): 1985-96.
115. Zhang W, et al. Vaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice. Journal of Virology 2010; 84(2): 1148-57.
116. Resch B, Resch E, Muller W. Should respiratory care in preterm infants include prophylaxis against respiratory syncytial virus infection? The case in favour. Paediatric Respiratory Reviews 2013; 14(2): 130-6.
117. Isaacs D. Should respiratory care in preterm infants include prophylaxis against respiratory syncytial virus? The case against. Paediatric Respiratory Reviews 2013; 14(2): 128-9.
118. Ng YT, et al. Encephalopathy associated with respiratory syncytial virus bronchiolitis. Journal of Child Neurology 2001; 16(2): 105-8.